a systemic disease with arthralgic pain and myalgias has been observed in 1 a lupus erythematosus like syndrome with skin rash and multiforme organ involvement is even less frequent the incidence of both ana and symptomatic disease under acebutolol is higher than under propranolol female patients are more likely to develop these symptoms than male patients some few cases of hepatotoxicity with increased liver enzymes alt ast have been seen altogether 5 to 6 of all patients treated have to discontinue acebutolol due to intolerable side effects when possible the treatment should be discontinued gradually in order to avoid a withdrawal syndrome with increased frequency of angina and even precipitation of myocardial infarction acebutolol is a cardioselective beta blocker with isa intrinsic sympathomimetic activity see article on pindolol it is therefore more suitable than non cardioselective beta blockers if a patient with asthma or chronic obstructive pulmonary disease copd needs treatment with a beta blocker for these reasons it may be a beta blocker of choice in inclusion in polypill strategies in doses lower than 800mg daily its constricting effects on the bronchial system and smooth muscle vessels are only 10 to 30 of those observed under propranolol treatment but